RWLK REWALK ROBOTICS LTD

ReWalk Robotics to Discuss Medicare’s Preliminary Payment Determination for ReWalk Personal Exoskeleton

ReWalk Robotics to Discuss Medicare’s Preliminary Payment Determination for ReWalk Personal Exoskeleton

Conference Call on Wednesday, November 8, 2023, at 8:30 a.m. EST

MARLBOROUGH, Mass., and BERLIN, and YOKNEAM ILLIT, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced that that it has scheduled a conference call for Wednesday, November 8, 2023 at 8:30 a.m. EST, to discuss Medicare’s preliminary payment determination for the ReWalk Personal Exoskeleton.

On Friday, November 3, the Centers for Medicare & Medicaid Services (“CMS”) released an agenda for the upcoming Healthcare Common Procedure Coding System (“HCPCS”) meeting on November 29, 2023, which includes an item to discuss the Medicare payment determination for the ReWalk Personal Prosthetic Exoskeleton system and provides a preliminary payment determination of $94,617.

Larry Jasinski, Chief Executive Officer, Jeannine Lynch, Vice President of Market Access and Strategy, and Mike Lawless, Chief Financial Officer, will host a conference call at 8:30 a.m. EST to discuss the potential impact of this announcement. To access the call, analysts and investors may utilize the following:

Toll free (U.S.)1-833-316-0561
International (U.S)1-412-317-0690
Germany0800-6647650
Israel1-80-9212373
Access CodePlease reference the “ReWalk Robotics Ltd. Call”
  

The conference call will be webcast live and the webcast can be accessed through a link on the Company’s website at rewalk.com in the "Investors" section, or through the following link: . An archived webcast will also be available on the company's website.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit . For more information on the AlterG systems, please visit .

ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. AlterG® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions.

ReWalk Media Relations:

LifeSci Communications

E:



ReWalk Investor Contact:

Mike Lawless

Chief Financial Officer

ReWalk Robotics Ltd

E: 



EN
07/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Successfully Closes on Strategic Partnership with Oramed

Lifeward Successfully Closes on Strategic Partnership with Oramed HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear...

 PRESS RELEASE

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Lt...

 PRESS RELEASE

Lifeward Receives Shareholder Approval to Close on Strategic Partnersh...

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed’s POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform’s clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovati...

 PRESS RELEASE

Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement

Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule"). To regain compliance with the...

 PRESS RELEASE

Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results...

Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and full year 2025 financial results before the markets open on Wednesday, March 18, 2026. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch